Evidence map›Paper›PMID 26228361›Full record

ArticleSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association

A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease.

Mahmoud H Mosli, Othman Al-Harbi, Brian G Feagan, Majid A Almadi

Open access · diamondAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Risk of neutropenia in inflammatory bowel disease patients treated with TNF inhibitors: A single-center, retrospective cohort study.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2020
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Mahmoud H MosliDepartment of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Medicine, University of Western Ontario, London, Ontario, Canada, .
Othman Al-Harbi
Brian G Feagan
Majid A Almadi
Western University · CAKing Khalid University Hospital · SAKing Saud University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this position statement from the Saudi Gastroenterology Association is to guide gastroenterologists on the use of tumor necrosis factor-alfa (TNF-α) antagonists for the treatment of the idiopathic inflammatory bowel diseases, Crohn's disease, and ulcerative colitis. In this article, we summarize the relevant literature regarding the safety and efficacy of TNF-α antagonists, highlight relevant safety concerns specific to the environment in Saudi Arabia, and provide specific recommendations for the use of these agents.

Indexed as

AdalimumabAntibodies, MonoclonalAnti-Inflammatory AgentsCertolizumab PegolHumansInflammatory Bowel DiseasesInfliximabSaudi ArabiaTumor Necrosis Factor-alphaAdalimumabAntibodies, MonoclonalAnti-Inflammatory AgentsCertolizumab PegolgolimumabInfliximabTumor Necrosis Factor-alpha

Identifiers

PMID26228361
PMCPMC4542416
OpenAlexW2170370314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.